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Cytolytic T lymphocytes (CTL) 1 can be generated in the mouse in response to 
appropriately "modified" syngeneic cells. Such CTL responses have been docu- 
mented using virus-infected (1, 2), chemically derivatized (3-8) and malignantly 
transformed (9, 1I) stimulator cells, as well as withH-2 identical responder and 
stimulator cells differing only at minor histocompatibility (H) loci (12, 13). All 
such CTL have been reported to lyse only target cells that possess both the 
appropriate "modifier" and the same H-2 K  and/or D  loci as the effector CTL. 
The H-2 restrictions for cytolysis in these systems appeared absolute in most 
studies  and  two  general hypotheses have been proposed  to  account for this 
phenomenon (1).  (a) The dual (immunological-physiological) interaction model 
postulates that CTL possess two functionally distinct receptor sites, both neces- 
sary for lysis. One recognizes the antigenic determinants of the viruses, chemi- 
cals, or minor H antigens and the other, coded for by the K or D region of the H-2 
complex of the CTL, is able to specifically and preferentially interact with the 
identical H-2 product on the target cell. (b) The altered-self hypothesis on the 
other hand proposes the immunological recognition by the CTL of new antigenic 
determinants created by the interaction of the modifier with a  D  or K  locus 
product of the target cells. This hypothesis postulates further that the immuno- 
logical dictionary of  these CTL is generally restricted to the recognition of  K and 
D  products in their native or modified forms. 
Experiments using F1 CTL against modified parental cells have led several 
authors to favor the altered-self hypothesis (1, 3, 5, 11, 12). Earlier studies from 
our laboratory with the trinitrophenyl (TNP) model are also consistent with the 
altered-self hypothesis (8). We observed that effectors generated to TNP synge- 
neic lymphoid cells could lyse TNP targets differing at H-2 from both effector 
and stimulator, although less efficiently than syngeneic targets. Such a finding 
would make the simple form of a dual recognition hypothesis unlikely, since no 
opportunity for like-like H-2 interaction is available under these circumstances. 
In addition, it was demonstrated that antisera against the H-2D or K  products 
* Supported by NIH grants CA-14723 and CA-09130. 
i Abbreviations  used in this paper: B6, C57BL/6; CRBC, chicken red blood cells; CTL, cytolytic T 
lymphocytes; SMEM-10, minimal essential medium supplemented with fetal calf serum and amino 
acids; TNP, trinitrophenyl; 8, Thy 1,2. 
THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  • VOLUME  144, 1976  1609 1610  CYTOLYSIS  OF  TNpoDERIVATIZED  H-2  INCOMPATIBLE  TARGETS 
on such TNP-modified allogeneic targets could inhibit cytolysis while antisera to 
H-2  specificities of the effector cells could not.  Finally,  several reports have 
shown that the lymphocyte populations of radiation chimeras unable to respond 
to the host H-2 haplotype can nevertheless be immunized in vitro by chemically 
or virally  modified cells bearing the  tolerated H-2  haplotype,  and  that  the 
immunized CTL lyse preferentially these cells in comparison to similarly modi- 
fied target cells syngeneic to the killer cells (14-16).  These experiments are evi- 
dence against a  requirement for like-like H-2  interactions between CTL and 
target. 
In this study, the phenomenon of cross-reactive lysis of  TNP-conjugated target 
cells has been investigated further. Also, the specificity of inhibition of lysis by 
anti-H-2 antisera was also reinvestigated. We have documented the CTL nature 
of the effector cells mediating lysis of TNP targets differing from the effector at 
H-2 and we have demonstrated that antisera directed only to K and D products, 
but not antisera against Ia or other cell surface markers, are able to inhibit such 
cytolysis in a  specific manner. 
Materials and Methods 
Mice.  6- to 12-wk-old male and female mice of the following strains were employed for these 
studies: A/J (H-2a), B10.BR (H-2k), BALB/c (H-2~), C57BL/6 [B6] (H-2b), and DBA/1 (H-2q). All 
were purchased from The Jackson Laboratory, Bar Harbor, Maine. 
Tumors.  The P815 (H-2Q masteeytoma, and L1210 (H-2 d) leukemia were maintained in DBA/ 
2 (H-2  d) mice. The EIA (H-2 b) leukemia was maintained in B6 mice. These tumors were carried in 
ascites form using biweekly intraperitoneal transfer. 
Antisera.  Alloantisera were raised by four to eight intraperitoneal injections of either tumor 
or lymphoid cells.  The donor-recipient combinations used and the specificity of each serum are 
given in the legend to Table III.  The anti-H-2 and anti-Ia sera were gifts of Dr.  Martin Dorf, 
Harvard Medical School, Boston, Mass. Anti-L1210 serum was the gift of Dr. Robert Humphreys, 
University of Massachusetts Medical School, Worcester, Mass. 
Generation  of Effector  Cells.  The  method used  to generate  cytotoxic effector cells to  TNP- 
derivatized stimulator cells has been described previously (8). Briefly, 7 ×  l0  s normal spleen cells 
were cultured at 37°C in 16-mm Linbro tissue culture wells (Linbro Chemical Co., New Haven, 
Conn.) together with 3 ×  l0  s TNP-derivatized, irradiated spleen cells for 5 days and then assayed. 
Anti-Thy 1.2 (0) plus Complement (C) Treatment.  The preparation, use, and specificity of anti- 
0 serum were the same as previously reported except that DNase was eliminated from the medium 
(17). 
Trinitrophenylation  of Chicken Red Blood Cells.  Fresh chicken red blood cells (CRBC) were 
washed three times with Eagle's minimum essential medium and 0.3 ml packed cells suspended in 
2  ml of cacodylate buffer  (0.28  M)  containing 40  mg trinitrobenzene sulfonic acid.  Cells  were 
incubated 10 min at 25°C,  then washed five times with MEM and resuspended to the appropriate 
concentration in minimal essential medium supplemented with fetal calf serum and amino acids 
(SMEM-10). 
slCr-Release Assay.  The  51Cr-release assay  used  in this study  and the  method of antisera 
inhibition have been previously described in detail (8).  In some experiments, 51Cr-labeled spleen 
targets were treated like effector cells with anti-8 serum plus C to enrich Ia-bearing B lymphocytes 
and then TNP derivatized as described (8). In those experiments involving competitive inhibition 
by unlabeled target cells, to 50/~l of 51Cr targets were added various numbers of unlabeled cells in 
50 ~l of SMEM-10, just before the addition of effector cells in a  100 ~1 vol. Therefore, all cultures 
contained a  total  of 200  ~1.  These  cultures  were  incubated for  4  h  at  37°C,  the  supernates 
harvested, and the percent specific release calculated as detailed elsewhere (8). All measurements 
were performed in duplicate or triplicate. The standard error of the mean was always <2-3%, and 
is  omitted  from  the  tables  and  figures  for clarity.  Differences of  >5%  are  almost  invariably 
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Regression Analysis.  Linear regression analysis of data and the Pearson's product moment 
correlation  were  determined  using a  Wang  760  computer  program  (Wang  Laboratories,  Inc., 
Tewksbury, Mass.). 
Results 
Cytotoxic Effector Cells Generated to TNP-Derivatized Syngeneic Stimulators 
Lyse  H-2  Compatible  and  H-2  Incompatible  TNP-Derivatized  Targets.  In 
Table I it can be seen that B6 spleen cells (H-2 ~) sensitized to TNP-derivatized 
B6 stimulators  (B6-TNP) lysed the EL4-TNP  (H-2 b) tumor target  or B6-TNP 
spleen target most effectively, but also demonstrated significant cytotoxicity on 
the H-2 incompatible tumor target PS15-TNP (H-2 d) and the A/J-TNP (H-2a), 
B10.BR-TNP  (H-2k),  and  DBA/1-TNP (H-2  q)  spleen targets.  This cytolysis of 
TNP-derivatized  targets  differing  from  the  effectors  at H-2  is  termed  cross- 
reactive lysis. 
In order to assess the relative effectiveness of cross-reactive as compared to H- 
2  identical  cell lysis,  effector cells were tested on both H-2 identical  and  H-2 
different TNP targets  at several effector/target  (E/T)  ratios.  Semilogarithmic 
plots  were  constructed  of "percent  specific 51Cr release"  vs.  E/T  ratio  of B6 
anti-B6-TNP  effectors on H-2  identical  (H-2 b)  or H-2  different  (H-2 ~)  TNP 
spleen targets.  By extrapolating the straight lines to equal percent release, an 
estimate of relative effector activity was obtained. The efficiency of lysis of the 
H-2 identical target was approximately five times that of lysis of the H-2 differ- 
ent target.  In several comparisons of this type, cross-reactive lysis usually was 
15-25% of syngeneic lysis. 
Cross-Reactive  Cytotoxicity Correlates  with the Extent of Cytotoxicity on the 
Syngeneic  Target.  Values  for  cross-reactive  and  syngeneic  target  cell  lysis 
mediated by the same effector cell pool were obtained from six to nine separate 
experiments and the data plotted as shown in Figs.  1 and 2. As can be seen in 
Fig. 1, when B6 effectors generated to B6-TNP were assayed on EL4-TNP (H-2 
identical targets) or P815-TNP (H-2 different targets), the data showed a direct 
correlation between the lysis on EL4-TNP and PS15-TNP and fit a straight line 
with r  =  0.96.  For a  similar comparison of BALB/c anti-BALB/c-TNP effectors 
on the same two tumor targets, r was 0.93. Excellent direct correlation between 
syngeneic and cross-reactive lysis was also observed using spleen cell targets. In 
Fig.  2,  B6 anti-B6-TNP  effectors were assayed on  B6-TNP and  BALB/c-TNP 
targets.  The  data  on  cytolysis again  fit  a  straight  line,  with r  =  0.89.  The 
reciprocal analysis of BALB/c anti-BALB/c-TNP on the same two spleen targets 
gave r  =  0.78. 
Cross-Reactive  Cytotoxicity  is Mediated by Cytolytic  T Lymphocytes.  Effector 
cells stimulated with TNP-derivatized syngeneic spleen cells were treated with 
anti-0 antiserum plus C just before assaying for cytotoxic activity. As has been 
previously reported  (4) and is shown in Table II,  lysis of H-2  identical  TNP- 
targets was virtually abolished by such treatment of effectors. The results were 
the same for cross-reactive lysis. Table II shows that cross-reactive lysis by B6 
anti-B6-TNP or BALB/c anti-BALB/c-TNP effectors on B10.BR-TNP targets is 
reduced to background by anti-0 plus C.  Similarly,  both syngeneic and cross- 
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TABLE  I 
Cytolysis of Tumor and Spleen Targets by Effectors Generated against TNP-Derivatized 
Syngeneic Stimulators* 
Exp.  RespoFcder  Stimulator 
no. 
Targets 
PS15-TNP  EL4-TNP 
P815  EL4  (H-2 d)  (H-2 b) 
1  BALB/c (H-2 el)  BALB/c-TNP  44.5  0  20.7  2.8 
B6 (H-2 ~)  B6-TNP  14.0  4.5  31.2  0 
B6-TNP  B6  A/J-TNP  A/J 
2  B6  B6-TNP  57.2  0  20.0  4.6 
A/J (H-2 ~)  A/J-TNP  10.0  0  34.3  0 
B10.BR- 
B6-TNP  B6  TNP  B10.BR 
(H-2 k) 
3  B6  B6-TNP  55.3  0  19.4  0 
B6-TNP 
DBA/1- 
TNP 
(H-2  q) 
4  B6  B6-TNP  75.1  58.8 
* Values are in percent specific release of 5~Cr, 
$ Effector to target ratio was 40:1. Spontaneous release from P815 and PS15-TNP was 10-18%; for 
EL4 and EIA-TNP, 18-26%; 31-39% for B6 and B6-TNP; 28-31% for A/J and A/J-TNP; B10.BR- 
TNP and B10.BR is 36-39%;  and 46% for DBA/1-TNP. 
0-bearing cells from the effector population. Treatment with anti-0 alone aug- 
mented killing slightly, while C alone had no effect. 
Alloantisera Directed to Target 1-1-2 Specificities Inhibit Cross-Reactive Cytol- 
ysis.  Schmitt-Verhulst et al. (3), and ourselves (8), have reported that alloanti- 
sera directed to the gene products of the K  and D  loci of the H-2 complex of the 
target cell inhibit cytolysis of the target by effector cells generated against TNP- 
derivatized  spleen  cells  that  are  H-2  identical  to  the  target.  We  have  also 
demonstrated that alloantisera directed to target H-2 specificities inhibit cross- 
reactive lysis (8).  However, evidence of the unique inhibitory capacity of anti- 
sera specific for H-2D and/or K products as opposed to other cell surface antigens 
was  deemed  necessary.  The  inhibitory  properties  of two  antisera  directed 
against membrane  specificities other than H-2D and H-2K were investigated. 
Freund  et  al.,  reported  recently that  the  DBA/2 leukemia  L1210  (H-2 ~) pos- 
sesses  a  high  concentration  of a  cell  surface  antigen  which  elicits  a  strong 
antibody response in the H-2  identical  C57BL/Ks (H-2 ~) strain  of mice. ~ The 
antigen detected by anti-L1210 antisera is also present in significant amounts on 
normal B lymphocytes. This antigen, since it elicits antibodies in mice identical 
2  Freund, J. G., A. Ahmed, R. E. Budd, M. E. Dorf, K. W. Sell,  W. E. Vannier, and R. E. 
Humphreys. 1976.  The L1210 leukemia cell  bears a B-lymphocyte-specific,  non-H-2-1inked alloan- 
tigen. J. lmmunol. In press. S.  J.  BURAKOFF,  R.  N.  GERMAIN~  AND  B.  BENACERRAF  1613 
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FIo.  1.  Correlation of the extent of cytotoxicity on H-2  identical and H-2  different TNP 
tumor targets expressed as percent specific release of 5~Cr. B6 (H-2 b) anti-B6-TNP (closed 
circles) and BALB/c (H-2 d) anti-BALB/c-TNP (open circles) effectors were assayed simul- 
taneously on EL4-TNP (H-2 ~) and P815-TNP (H-2 d) targets. The correlation coefficient was 
determined and the data points were fitted to a straight line by linear regression analysis. 
Each point represents a separate experiment and the assays were performed at an effector 
to target ratio of 40:1. 
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FIO.  2.  Correlation of the extent of cytotoxicity on H-2 identical and H-2 different TNP 
spleen targets expressed as percent specific release of 5~Cr. B6 (H-2 ~) anti-B6-TNP (closed 
circles) and BALB/c anti-BALB/c-TNP (open circles) effectors were assayed simultaneously 
on B6-TNP and BALB/c-TNP targets. The correlation coefficient was determined and the 
data points were fitted to a  straight line by linear regression analysis. Each point repre- 
sents a separate experiment and the assays were performed at an effector to target ratio of 
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TABLE  II 
Sensitivity of Effector cells to Anti-O Plus C Treatment 
% Specific 
Exp.  Responder  Stimulator  Effector  Cell  Target*  Release of 
no.  Treatment  51Cr 
1  B10.BR (1-1-2  k)  B10.BR-TNP  None  B10.BR-TNP  68.5 
B10.BR  B10.BR-TNP  a 0 Plus C  B10.BR-TNP  11.9 
2  B6 (H-2 ~)  B6-TNP  None  B10.BR-TNP  12.7 
B6  B6-TNP  a 0 Plus C  B10.BR-TNP  1.7 
BALB/c (H-2 d)  BALB/c-TNP  None  B10.BR-TNP  11.0 
BALB/c  BALB/c-TNP  a  0 Plus C  B10.BR-TNP  0.4 
BALB/c  BALB/c-TNP  None  L1210-TNP  38.6 
(H-24) 
BALB/c  BALB/c-TNP  a 0 Plus C  L1210-TNP  2.4 
B6  B6-TNP  None  L1210-TNP  21.5 
B6  B6.TNP  a  0 Plus C  L1210-TNP  0.5 
* B10.BR-TNP spleen cells were treated with anti-0 antiserum plus C and the remaining viable 
cells were used as target cells. Spontaneous release of L1210 targets was 9-16% and B10.BR-TNP 
targets was 33-40%.  Effector to target ratio was 40:1. 
with the tumor at H-2, is not coded for by the H-2 complex. Such a potent anti- 
L1210 antiserum was used to determine if antibodies to non-H-2 cell surface 
markers on target cells could inhibit lysis. Table III shows that neither synge- 
neic nor more importantly cross-reactive lysis can be inhibited by an antiserum 
to the L1210 non-H-2 alloantigen, even though this antiserum had a greater C- 
dependent lytic titer on L1210 cells than the anti-H-2D d  antiserum endowed 
with inhibitory properties. 
The specificity of inhibition of syngeneic and cross-reactive lysis by alloanti- 
sera to H-2 D  and K  was also confirmed by attempting to inhibit lysis using an 
antiserum  to  other  H-2  products,  namely Ia  antigens.  To  insure  maximal 
representation of Ia on target cells, B10.BR spleen cells were treated with anti-0 
serum plus C and only the remaining viable cells used as targets. After such 
treatment 80-90%  of the  viable  cells  were  surface  immunoglobulin and  Ia  k 
positive. Table III documents that cross-reactive lysis of such "B-lymphocyte" 
B10.BR-TNP targets by BALB/c anti-BALB/c-TNP or B6 anti-B6-TNP effectors 
was not inhibited by an antiserum to the/-region gene products of the H-2 k 
haplotype of the B10.BR-TNP target, in contrast to the inhibitory properties of 
an antiserum to the H-2 k D  and K  antigens with equivalent cytotoxic titer. 
Failure  to  Detect  TNP-Specific  CTL  Using  TNP-CRBC  as  Inhibitors  of 
Cytolysis.  The ability of anti-H-2 D or K antisera to inhibit cross-reactive lysis 
indicated a probable functional role for the D and K  gene products in cytolysis. 
However, such data did not preclude the possibility, suggested by Dennert and 
Hatlen, that such cross-reactive killers were primarily "hapten specific," i.e. 
recognized the TNP determinant via their antigen receptors, and that the H-2 D 
or K  restrictions concerned other features of the cell-cell interaction necessary S.  J.  BURAKOFF,  R.  N.  GERMAIN,  AND  B.  BENACERRAF  1615 
TABLe. III 
Inhibition of Cytolysis by Antisera Directed to Cell Surface antigens of the Targets* 
Exp.  Responder  Stimulator  Target  Controls  a-L1210  a-H-2D  d 
no. 
1  BALB/c  BALB/c-TNP  L1210-TNP  16.5  20.9  4.7 
B6  B6-TNP  L1210-TNP  11.1  15.9  7.2 
B10.BR  B10.BR-TNP  L1210-TNP  30.7  33.7  9.9 
Control  a-Ia  k  a-H-2KkD  k 
2  B10.BR  B10.BR-TNP  B10.BR-TNP§  61.5  43.3  7.9 
3  BALB/c  BALB/c-TNP  B10.BR-TNP  24.6  19.6  5.1 
B6  B6-TNP  B10.BR-TNP  22.6  21.7  0 
* Values are in percent specific release of 51Cr. 
S Control consisted of either MEM or NMS at a final dilution  of 1:12. Anti-L1210 antiserum  is 
C57BL/Ks (11-2  ~) anti-L1210 (H-2 ~); with a lytic titer of 1/960; anti-Ia  k  is A.TH anti-A.TL with a 
lytic titer of 1/1,280; anti-H-2D d is (B10.LP.R III)Fl anti-18R with a lytic titer of 1/2,560; and 
anti-H-2K~D  k is (B10 x A.TH)F1 anti-B10.BR with a lytic titer of 1/1,280. All antisera are at a 
final dilution of 1:12. 
§ B10.BR-TNP spleen cells were treated with anti-0 antiserum plus C and the remaining  viable 
cells were used as targets.  80-90% of the remaining spleen cells were lysed by anti-Ia  k antiserum 
plus C. Spontaneous release of L1210-TNP  is 16 and 49% for B10.BR-TNP. Effector to target ratio 
was 40:1, except for B10.BR effectors tested on B10.BR-TNP target,  where the ratio was 5:1. 
for lysis (6, 7). To evaluate this possibility, attempts were made to inhibit lysis of 
TNP  targets  using  unlabeled  TNP-CRBC  as  potential  competitors  for  TNP- 
specific receptor binding in the 5'Cr-release assay. TNP-CRBC were derivatized 
by Dennert's method (6) and various concentrations of these cells were added to 
effectors and 51Cr-labeled targets.  No inhibition  of syngeneic or cross-reactive 
lysis of TNP  derivatized  at  ratios  up  to and  including  120  TNP-CRBC:I 5'Cr 
target  cell  was observed.  A  ratio  of 240:1  nonspecifically inhibited  allogeneic 
killing of non-TNP-derivatized targets and therefore was not informative. 
Inhibition of Cytolysis  by Competition  with Cold Spleen Targets.  Cold tar- 
get  competition  experiments  with  unlabeled  spleen  cells  were  performed  to 
determine whether the CTL-mediating lysis of H-2 different TNP-targets belong 
to the same set of CTL as those mediating lysis of syngeneic TNP targets,  or 
whether  they  were  totally  distinct  effectors.  Fig.  3  demonstrates  that  the 
cytolysis of BALB/c-TNP 51Cr-labeled targets by BALB/c effectors can only be 
inhibited  by the presence  of TNP-derivatized nonradiolabeled  BALB/c spleen 
cells. B6 effectors assayed on ~Cr-labeled B6-TNP targets can also be inhibited 
only by TNP-derivatized non-5~Cr-labeled spleen cells that are syngeneic to the 
target cell. 
Cross-reactive cytolysis of B6 effectors generated to B6-TNP stimulators and 
assayed on BALB/c-TNP ~Cr targets,  however,  can be inhibited  similarly by 
BALB/c-TNP and  B6-TNP unlabeled  targets.  Data are given for a  ratio of 40 
unlabeled  spleen  cells:l  ~Cr-labeled  spleen  cell,  but  qualitatively  identical 
results were obtained at a  20:1 ratio. These findings indicate that the same CTL 
population responsible for the lysis of H-2 syngeneic TNP targets also lyse H-2 
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FIG.  3.  Inhibition of cytolysis by competition with nonradiolabeled spleen targets.  Effec- 
tors were assayed in the absence of nonradiolabeled spleen cells (control response) or in the 
presence of a ratio of 40 nonradiolabeled spleen cells: 1 5~Cr-labeled spleen target. The control 
response for BALB/c anti-BALB/c-TNP assayed on BALB/c-TNP was 27% specific release, 
63%  for  B6  anti-B6-TNP  assayed  on  B6-TNP,  and  37%  for B6  anti-B6-TNP assayed  on 
BALB/c-TNP. Effector to 51Cr target ratio was 40:1. Spontaneous release ranged between 39 
and 48%. 
Discussion 
Normal spleen cells, when cultured with irradiated  TNP-derivatized  synge- 
neic spleen cells, develop cytotoxic effectors that  lyse most effectively a  TNP- 
derivatized  target  that  is  H-2  compatible  with  the  effector;  these  cytolytic 
effectors,  however,  also lyse to  a  lesser  extent  TNP  tumor  and  TNP  spleen 
targets that do not share products of the H-2 K  orD loci with the effector. Cross- 
reactive lysis correlates directly with the degree of cytolysis seen on the TNP- 
derivatized syngeneic target, it appears to be mediated by ~-bearing cells and it 
is inhibited by antisera to the K and/or D loci of the target cell and not by several 
other  antisera  to  non-D  or  non-K  surface  antigens.  Nonradiolabeled  TNP- 
derivatized lymphoid cells syngeneic to either the stimulator or the target are 
able to competitively inhibit cross-reactive lysis, while TNP-CRBC are unable to 
specifically inhibit cytolysis even at a  120:1 ratio to the target cells. 
The high  positive correlation  noted between lysis of H-2  identical  and H-2 
nonidentical target cells mediated by the same effector population indicates that 
cross-reactive lysis is not an independent, randomly occurring event. Shearer et 
al. (4) have observed that effector cells sensitized with TNP-modified autologous 
spleen cells demonstrated a significant degree of lysis of non-H-2-matched TNP- 
modified tumor but not lymphoid targets. They suggest that this cross-reactivity 
is due to TNP-modified tumor targets being more sensitive to nonspecific lysis 
by cytotoxic effector cells. We have noted cross-reactive lysis on TNP-derivatized 
spleen as well as on TNP tumor targets.  The fact that this cross-reactivity is S.  J.  BURAKOFF,  R.  N.  GERMAIN,  AND  B.  BENACERRAF  1617 
inhibited only by antisera directed to the H-2 K  and D  gene products makes it 
very improbable that we are simply observing nonspecific lysis. The hypothesis 
that "weak" B6 effectors to unmodified H-2 ~ alloantigens  are generated in our 
cultures,  which are detected on more '~lysable" BALB/c-TNP targets in prefer- 
ence to BALB/c targets, is also unlikely to be valid, since competitive inhibition 
should  then occur with unlabeled  BALB/c cells as well as withBALB/c-TNP 
spleen cells. No such inhibition was observed. 
It is not clear why cross-reactive lysis has not been reported by others.  The 
quantitative  relationships  between syngeneic and  cross-reactive lysis demon- 
strated  in  this  study  may  account  for  the  absence  of such  killing  in  most 
previous experiments with the TNP model, since the level of syngeneic lysis in 
those  studies  rarely  exceeded 35%,  the  minimum  level  needed to  see cross- 
reactive  killing.  In  addition,  we have  noted  (unpublished  observations)  that 
CTL from mice bearing certain H-2 haplotypes fail to show cross-reactive lysis 
even though  syngeneic lysis is greater than 80%.  Thus,  the particular  mouse 
strain investigated may be critically responsible for the differences. It should be 
noted,  however,  that  in several virus models investigated  using some of the 
same strains as reported here, e.g. BALB/c, little or no cross-reactive lysis was 
noted even with specific release  exceeding 70%  on H-2  identical  targets  (18). 
The reason for this marked difference between viral and chemical systems is not 
apparent but may relate to the possibly more extensive modifications of the H-2 
K  or D  products of the target  cells induced by TNP conjugation  compared to 
interaction  with viral products. 
The evidence supporting the relevance of blocking data with specific anti-H-2 
antisera to the analysis of the functional role of H-2 D  and K  products in CTL 
target interaction is substantial.  Previous reports in allogeneic systems as well 
as in the TNP model clearly show that only antisera directed to gene products of 
the H-2 complex that can be shown by genetic analysis to be important in CTL- 
target  interaction  are  able to inhibit  cytolysis (3,  8,  19).  Antisera  against  Ia 
antigens  do not block cytolysis by CTL specific for modified syngeneic targets 
(3). This result is not unexpected since I region products have not been found to 
be involved in the  specificity of CTL against  modified syngeneic targets.  We 
have  extended  these  observations  to  cross-reactive  lysis  and  shown  that  an 
antiserum to a cell-surface alloantigen distinct from H-2 products fails to inhibit 
such lysis, whereas an anti-H-2D d antiserum is inhibitory.  Similarly, an anti- 
Ia  k antiserum shows no effect on B6 anti-B6-TNP CTL-mediated lysis of B10.BR- 
TNP cells while an anti-H-2KkD  k antiserum is inhibitory.  Such results make it 
highly improbable that blocking of CTL by anti-H-2 antisera represent a  non- 
specific effect on the target  membrane,  reducing target  lysability, or alterna- 
tively that  such  inhibition  results  from  nonspecific steric  hindrance  of CTL- 
target  interaction  due to large  amounts of unrelated  antibody present on the 
target  cell  membrane.  These  and  previous data  on  alloantisera  inhibition  of 
cross-reactive lysis also demonstrate that the antisera inhibit by acting on the 
target cells and not the CTL, since antisera  against effector CTL cannot block 
cross-reactive lysis (8). 
As stated in the introduction,  two models have been proposed to explain the 
H-2 restriction of effector-target interaction  for effectors generated to modified 
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dual recognition hypothesis as presently stated cannot account adequately for 
our observations of cytolysis between H-2 incompatible effector and target cells, 
nor for the observations of others with radiation chimeras  (14-16).  In these 
chimeras, cytotoxic effectors could be induced against virally infected or TNP- 
modified H-2 incompatible tolerated target cells. In both situations, cytolysis is 
observed with effector and target cells differing at H-2 D  and K, precluding a 
strict requirement for H-2 D or K  identity for cell-cell interaction. The possibil- 
ity that much less efficient, but still detectable, "physiologic interaction" could 
occur between effector  H-2 recognition structures and target cell allogeneic H-2 
markers is made unlikely by the finding that in the chimeric systems killing of 
H-2  different targets matched to the stimulator cells is considerably greater 
than killing of targets matched to the effector H-2  (14-16).  If "cross-reactive" 
physiologic interaction were the explanation for the apparent violation of the H- 
2  identity rule, killing of the latter targets should at least equal that of the H-2 
different targets. Since the opposite is found, the cross-reactivity observed in our 
experiments is consistent with the altered-self hypothesis, i.e., the formation of 
new antigenic determinants involving TNP modification of H-2 D or K. Effector 
cells generated to TNP-derivatized syngeneic cells would recognize shared deter- 
minants resulting from TNP derivatization of H-2  different targets.  If cross- 
reactivity occurs for this reason (i.e., shared antigens), one would predict that 
unlabeled TNP spleen cells syngeneic to the stimulator as well as the non-H-2- 
matched target would competitively inhibit cross-reactive lysis. This was shown 
to be the case. 51Cr release by B6 effectors generated to B6-TNP stimulators and 
assayed on BALB/c-TNP targets  was inhibited  equally well by B6-TNP  and 
BALB/c-TNP spleen cells. Thus, the data suggest that the antigens recognized 
on the BALB/c-TNP targets were the same or similar to the antigens recognized 
on the B6-TNP  targets  (and stimulators),  since B6-TNP  could competitively 
inhibit this cross-reactive lysis. This would imply that a subset of the clones that 
lyse the H-2 compatible targets constitute the subpopulation of CTL that lyses 
the H-2 incompatible targets.  Since allogeneic TNP cold targets do not inhibit 
lysis of syngeneic TNP targets, this subset is most likely a small fraction of the 
total CTL population (i.e.,  15-25%). 
In conclusion, it would appear that our data on cross-reactive lysis of TNP- 
conjugated targets is most consistant with the altered-self hypothesis. To ac- 
count  for  our  data  and  that  involving  chimeras,  the  dual  (immunological- 
physiological) interaction model would require the effector cell to bear, besides 
an  antigen-specific receptor,  a  surface  component  that  could  interact  with 
histoincompatible target  cells,  a  possibility  for  which little  supporting  data 
exists. 
Summary 
Normal spleen cells,  when cultured with irradiated trinitrophenyl  (TNP)- 
derivatized syngeneic spleen cells,  develop cytotoxic effectors that lyse most 
effectively a  TNP-derivatized target that is H-2  compatible with the effector. 
However, these effectors also lyse to a lesser extent TNP tumor and TNP spleen 
targets that are H-2 incompatible. This cross-reactive lysis correlates with the 
degree of cytolysis seen on the TNP-derivatized syngeneic target; it appears to S.  J.  BURAKOFF,  R.  N.  GERMAIN,  AND  B.  BENACERRAF  1619 
be mediated by Thy 1.2-bearing cells and is inhibited by antisera to the K  and/or 
D  loci of the target cell and not by antisera to non-K or non-I) surface antigens. 
Nonradiolabeled TNP-derivatized lymphoid cells syngeneic to either the stimu- 
lator or the target are able to competitively inhibit cross-reactive lysis,  while 
TNP chicken red blood cells are unable to specifically inhibit lysis. These data 
on cross-reactive lysis of TNP-conjugated targets are most consistent with the 
altered-self  hypothesis. 
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